AIMS: To determine the incidence and prognostic value of p53 immunopositivity in resectable distal bile duct carcinoma (DBDC). METHODS: Forty-seven paraffin-embedded archival tumour samples of patients with DBDC, who underwent subtotal pancreatoduodenectomy from 1985 to 1996, were immunohistochemically examined for p53 positivity, using the anti-p53 antibody D07. RESULTS: Nineteen (40%) of the 47 tumours demonstrated positive (>30%) p53 protein immunostaining. Focally positive or negative staining was seen in the remaining 28 (60%) cases. Patients in this low p53 category survived significantly longer than those in the high p53 category, with median survival durations of 29 and 13 months respectively (P=0. 039). p53 positivity was independent of age, sex, tumour size, radicality of resection, histopathological grading, lymph-node status, perineural invasion and vasoinvasive growth. CONCLUSIONS: This study indicates that low (0-30%) p53 expression is a favourable prognostic factor in patients with resected DBDC. Copyright 1999 W.B. Saunders Company Ltd.
AIMS: To determine the incidence and prognostic value of p53 immunopositivity in resectable distal bile duct carcinoma (DBDC). METHODS: Forty-seven paraffin-embedded archival tumour samples of patients with DBDC, who underwent subtotal pancreatoduodenectomy from 1985 to 1996, were immunohistochemically examined for p53 positivity, using the anti-p53 antibody D07. RESULTS: Nineteen (40%) of the 47 tumours demonstrated positive (>30%) p53 protein immunostaining. Focally positive or negative staining was seen in the remaining 28 (60%) cases. Patients in this low p53 category survived significantly longer than those in the high p53 category, with median survival durations of 29 and 13 months respectively (P=0. 039). p53 positivity was independent of age, sex, tumour size, radicality of resection, histopathological grading, lymph-node status, perineural invasion and vasoinvasive growth. CONCLUSIONS: This study indicates that low (0-30%) p53 expression is a favourable prognostic factor in patients with resected DBDC. Copyright 1999 W.B. Saunders Company Ltd.
Authors: Rosa B Schmuck; Cynthia V de Carvalho-Fischer; Christopher Neumann; Johann Pratschke; Marcus Bahra Journal: Cancer Med Date: 2015-12-09 Impact factor: 4.452
Authors: Pina Ziranu; Eleonora Lai; Marta Schirripa; Marco Puzzoni; Mara Persano; Andrea Pretta; Giada Munari; Nicole Liscia; Valeria Pusceddu; Fotios Loupakis; Laura Demurtas; Michela Libertini; Stefano Mariani; Marco Migliari; Marco Dubois; Riccardo Giampieri; Giovanni Sotgiu; Angelo Paolo Dei Tos; Sara Lonardi; Alberto Zaniboni; Matteo Fassan; Mario Scartozzi Journal: Target Oncol Date: 2021-05-10 Impact factor: 4.493